You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 康寧傑瑞製藥-B漲超14%,股價一個月累漲106%
uSMART盈立智投 05-21 10:57

uSMART盈立智投5月21日消息,週五港股早盤,康寧傑瑞製藥-B高開高走,截至10:53,康寧傑瑞製藥-B漲14.55%,報20.55港元,值得注意的是,自4月21日以來,該股已累計漲逾106%。

5月20日康寧傑瑞製藥-B公佈,將於2021年美國臨牀腫瘤學會年會呈列KN046 (一種重組人源化PD-L1/CTLA-4雙特異性抗體)及KN026(一種基於Fc的抗 HER2雙特異性抗體)的研究結果,美國臨牀腫瘤學會爲醫生及腫瘤學專業人士關愛癌症患者的世界領先專業機構。

興業證券早前發佈研報稱,康寧傑瑞製藥的四大核心產品差異化優勢突出,市場空間廣闊:PD-1+CTLA-4聯合療法潛力大,但存在高毒性問題,KN046有望通過減毒增效,成爲下一代免疫治療的基石藥物。興業證券預計4款產品有望於2029年達到銷售峯值155.45億元,扣除CSO費用後爲142.36億元。

興業證券首予康寧傑瑞製藥-B"買入"評級,目標價27.15港元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account